Back to top

blockchain: Archive

Zacks Equity Research

Is MSIF International Opportunities I (MIOIX) a Strong Mutual Fund Pick Right Now?

Mutual Fund Report for MIOIX

MIOIXNegative Net Change

Zacks Equity Research

Is Schwab Balanced Fund (SWOBX) a Strong Mutual Fund Pick Right Now?

Mutual Fund Report for SWOBX

SWOBXNegative Net Change

Zacks Equity Research

Is VWESX a Strong Bond Fund Right Now?

MF Bond Report for VWESX

VWESXNegative Net Change

Zacks Equity Research

Is Invesco Dynamic Biotechnology & Genome ETF (PBE) a Strong ETF Right Now?

Smart Beta ETF report for PBE

PBEPositive Net Change VRTXNegative Net Change IBBPositive Net Change CCXIPositive Net Change CTLTPositive Net Change XBIPositive Net Change

Zacks Equity Research

Is WisdomTree Emerging Markets High Dividend ETF (DEM) a Strong ETF Right Now?

Smart Beta ETF report for DEM

DEMPositive Net Change IEMGPositive Net Change VWOPositive Net Change

Zacks Equity Research

Is iShares ESG Aware MSCI USA ETF (ESGU) a Strong ETF Right Now?

Smart Beta ETF report for ESGU

ESGUNegative Net Change AMZNNegative Net Change AAPLNegative Net Change MSFTNegative Net Change ESGDPositive Net Change ESGVNegative Net Change

Zacks Equity Research

Is First Trust Rising Dividend Achievers ETF (RDVY) a Strong ETF Right Now?

Smart Beta ETF report for RDVY

RDVYNegative Net Change AAPLNegative Net Change JEFNegative Net Change WSMNegative Net Change VTVNegative Net Change IWDNegative Net Change

Zacks Equity Research

Is ProShares S&P 500 Dividend Aristocrats ETF (NOBL) a Strong ETF Right Now?

Smart Beta ETF report for NOBL

NOBLNegative Net Change ADMPositive Net Change GWWNegative Net Change ALBPositive Net Change VIGPositive Net Change DGRONegative Net Change

Supriyo Bose

Generac Holdings (GNRC) Moves 3.2% Higher: Will This Strength Last?

Generac Holdings (GNRC) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

GNRCPositive Net Change BWNegative Net Change

Zacks Equity Research

Allied Motion (AMOT) Moves 5.1% Higher: Will This Strength Last?

Allied Motion (AMOT) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

AMOTPositive Net Change STNegative Net Change

Zacks Equity Research

Is Atmos (ATO) a Solid Growth Stock? 3 Reasons to Think "Yes"

Atmos (ATO) is well positioned to outperform the market, as it exhibits above-average growth in financials.

ATOPositive Net Change

Zacks Equity Research

Looking for a Growth Stock? 3 Reasons Why Chico's (CHS) is a Solid Choice

Chico's (CHS) could produce exceptional returns because of its solid growth attributes.

CHSPositive Net Change

Zacks Equity Research

Here is Why Growth Investors Should Buy e.l.f. Beauty (ELF) Now

e.l.f. Beauty (ELF) possesses solid growth attributes, which could help it handily outperform the market.

ELFPositive Net Change

Zacks Equity Research

Here is Why Growth Investors Should Buy Moog (MOG.A) Now

Moog (MOG.A) is well positioned to outperform the market, as it exhibits above-average growth in financials.

MOG.ANegative Net Change

Zacks Equity Research

Ryerson (RYI) is an Incredible Growth Stock: 3 Reasons Why

Ryerson (RYI) possesses solid growth attributes, which could help it handily outperform the market.

RYIPositive Net Change

Zacks Equity Research

Strength Seen in Cano Health, Inc. (CANO): Can Its 32.2% Jump Turn into More Strength?

Cano Health, Inc. (CANO) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Zacks Equity Research

Protagonist Therapeutics (PTGX) Upgraded to Buy: What Does It Mean for the Stock?

Protagonist Therapeutics (PTGX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

PTGXPositive Net Change

Zacks Equity Research

Syros Pharmaceuticals, Inc. (SYRS) Upgraded to Buy: What Does It Mean for the Stock?

Syros Pharmaceuticals, Inc. (SYRS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.